Oncology Drug Lag: Unapproved Drugs and Sponsor-Recruitment Rounds | Policy & Market Intelligence

Description

List of Tables

Drug lag - the gap between when a cancer medicine is available in the United States or Europe and when Japanese patients can receive it - was supposed to be a solved problem. Approval times at PMDA have converged with Western regulators, and the era of decade-long delays is over. Yet the lag has mutated rather than disappeared. The modern problem is not slow review but absent sponsorship: drugs approved everywhere else for which no company files in Japan at all, because the commercial calculation - price trajectory, indication economics, partner availability, organizational overhead - does not close. Japanese oncologists call the result drug loss, and the government now treats it as policy failure rather than market noise.

The policy response has become unusually direct. MHLW publishes lists of unapproved oncology drugs with medical need and runs sponsor-recruitment rounds, effectively advertising for companies willing to file. Priority review is offered for overseas-approved alternatives. Conditional approval pathways accept smaller Japanese datasets. Medical societies and patient groups can trigger review of unapproved drugs through a request system. Each mechanism has produced filings, and each has also revealed its limits: recruitment rounds find sponsors for some products and silence for others, and the economics that caused the absence do not disappear because a committee asks.

This report provides the working map of the problem and the responses. It defines and measures lag and loss precisely, catalogs the unapproved oncology inventory by class and company, and profiles the policy machinery: the lists, the recruitment rounds, the review incentives, and the request system. It examines why companies decline Japan - pricing exposure, trial economics, organizational prerequisites - with named case structures, and it maps the consequences: physician advocacy, investigator-initiated trials, and the business-development openings the gap creates for domestic firms seeking assets. Comparative chapters place Japan's policy tools against those of other markets.

The report serves foreign biotechs assessing whether Japan's incentives now close the gap, domestic companies hunting in-licensable unapproved assets, CROs positioning for recruitment-round development work, and investors tracking a policy experiment in real time.

Scope and Coverage: The report covers oncology drug lag and drug loss in Japan: measurement, the unapproved inventory, policy responses including sponsor-recruitment rounds, company decision analysis, and access consequences. International comparison covers lag-reduction policy in other major markets.

Report Highlights:

Precise definitions and measurement of approval lag versus sponsorship absence
The unapproved oncology drug inventory organized by class and company
Policy machinery: MHLW lists, recruitment rounds, and review incentives
Case structures for why companies file late or not at all
Access consequences and the physician-led response system
Business-development opportunities created by the unapproved inventory

Product Code: JPH-050

Table of Content

1. Executive Summary

2. Oncology Drug Lag: Policy and Institutional Framework

3. Reimbursement, Pricing, and Funding Flows

4. Provider and Operator Landscape: Structure and Economics

5. Workforce and Capacity Analysis

6. Technology and Vendor Ecosystem

7. International Comparison: US, EU5, and China

8. Implications for Entrants and Investors

9. Appendix: Methodology and Sources

Companies Mentioned

Boehringer Ingelheim (DE) - solo Hernexeos filing as a lag-reduction counterexample. Servier (FR) - products without Japanese development or NHI listing. BeiGene (CN) - tislelizumab and zanubrutinib Japan entry decisions in progress. Innovent (CN) - sintilimab and pipeline assets not yet filed in Japan. Genmab (DK) - Epkinly and Tivdak Japan pathways via partners. Blueprint Medicines (US) - targeted-therapy assets with historically delayed Japan programs. Nobelpharma (JP) - specialist in developing unapproved drugs for the Japanese market. SymBio Pharmaceuticals (JP) - in-licensing model for unapproved oncology and hematology drugs. CMIC Holdings (JP) - CRO supporting sponsor-recruitment development programs. Ono Pharmaceutical (JP) - domestic sponsor candidate for unapproved oncology assets.

Product Code: JPH-050

List of Tables

Table 1. Drug lag and drug loss: definitions and measurement frameworks
Table 2. Oncology approval lag versus the US and EU: comparative framework
Table 3. MHLW unapproved drug lists: construction and update process
Table 4. Share of globally approved oncology drugs available in Japan
Table 5. Time-to-approval distribution for oncology drugs in Japan
Table 6. Indication-level lag within approved products
Table 7. Pediatric oncology drug lag
Table 8. Drug-loss countermeasure policy timeline
Table 9. First sponsor-recruitment round: product list and process
Table 10. Second sponsor-recruitment round: product list and process
Table 11. Priority review for overseas-approved alternatives: mechanism design
Table 12. Conditional early approval as a lag-reduction tool
Table 13. Medical-need request system for unapproved drugs
Table 14. Compassionate use and expanded access mechanisms in Japan
Table 15. Checkpoint inhibitor indications not available in Japan
Table 16. Targeted therapies approved abroad but unfiled in Japan
Table 17. ADC indications not yet available in Japan
Table 18. Hematology products without Japan filings
Table 19. Rare cancer therapies and the lag problem
Table 20. Servier portfolio: products without Japanese development or listing
Table 21. Genmab Epkinly and Tivdak Japan pathways
Table 22. Blueprint Medicines targeted oncology status in Japan
Table 23. Innovent and Chinese-origin assets not filed in Japan
Table 24. BeiGene tislelizumab and zanubrutinib Japan decisions
Table 25. Commercial rationale framework for skipping Japan
Table 26. Pricing environment as a lag driver
Table 27. Trial infrastructure and enrollment barriers
Table 28. Japanese data requirements and bridging burden
Table 29. MAH and organizational prerequisites for filing
Table 30. Partner availability and licensing friction
Table 31. Portfolio prioritization inside global companies
Table 32. Small-population indication economics
Table 33. Patient access consequences: clinical framework
Table 34. Physician society advocacy for unapproved drugs
Table 35. Patient organization activity on drug loss
Table 36. Investigator-initiated trial responses to unapproved needs
Table 37. CRO and development-service opportunities from lag
Table 38. BD opportunities for domestic firms seeking unapproved assets
Table 39. Hospital-level access pathways for unapproved drugs
Table 40. UK and EU early-access mechanisms as comparators
Table 41. US-Japan development integration trends
Table 42. Policy trajectory for lag reduction
Table 43. Japan-first and simultaneous development incentives
Table 44. RWD use in lag-reduction filings
Table 45. PMDA capacity and review speed initiatives
Table 46. Anticipated filing wave from recruitment rounds
Table 47. Watchlist: high-profile unapproved oncology drugs
Table 48. Lag scenario framework under alternative policy paths
Table 49. Implications for global development planning
Table 50. Report methodology and evidence sources

List of Figures

Figure 1. Lag versus loss definitional schematic
Figure 2. Approval lag measurement framework
Figure 3. MHLW list construction process flow
Figure 4. Global-to-Japan availability map for oncology drugs
Figure 5. Time-to-approval distribution schematic
Figure 6. Indication-level lag anatomy
Figure 7. Pediatric oncology lag map
Figure 8. Drug-loss policy timeline
Figure 9. First recruitment round process flow
Figure 10. Second recruitment round process flow
Figure 11. Priority review incentive mechanism diagram
Figure 12. Conditional approval pathway for lag reduction
Figure 13. Medical-need request system flow
Figure 14. Compassionate use mechanism map
Figure 15. Checkpoint inhibitor indication gap map
Figure 16. Targeted therapy unapproved inventory map
Figure 17. ADC indication gap map
Figure 18. Hematology filing gap map
Figure 19. Rare cancer therapy access map
Figure 20. Servier non-listed portfolio anatomy
Figure 21. Genmab Japan pathway map
Figure 22. Blueprint Medicines Japan status map
Figure 23. Chinese-origin asset filing status map
Figure 24. BeiGene Japan decision framework
Figure 25. Skip-Japan decision tree
Figure 26. Pricing exposure integration in filing decisions
Figure 27. Trial infrastructure barrier map
Figure 28. Bridging burden schematic
Figure 29. MAH prerequisite map
Figure 30. Partner friction anatomy
Figure 31. Global portfolio prioritization flow
Figure 32. Small-indication economics framework
Figure 33. Patient access consequence pathway
Figure 34. Physician society advocacy map
Figure 35. Patient organization activity map
Figure 36. Investigator-initiated trial response structure
Figure 37. CRO opportunity map from lag
Figure 38. Domestic BD opportunity map from unapproved inventory
Figure 39. Hospital access pathway flow for unapproved drugs
Figure 40. Early-access mechanism comparison map
Figure 41. US-Japan development integration trend schematic
Figure 42. Policy trajectory map
Figure 43. Japan-first incentive structure
Figure 44. RWD filing pathway schematic
Figure 45. PMDA capacity initiative map
Figure 46. Recruitment-round filing wave projection structure
Figure 47. Unapproved drug watchlist framework
Figure 48. Lag scenario tree
Figure 49. Global development planning implication map
Figure 50. Report methodology schematic

Oncology Drug Lag: Unapproved Drugs and Sponsor-Recruitment Rounds | Policy & Market Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. Oncology Drug Lag: Policy and Institutional Framework

3. Reimbursement, Pricing, and Funding Flows

4. Provider and Operator Landscape: Structure and Economics

5. Workforce and Capacity Analysis

6. Technology and Vendor Ecosystem

7. International Comparison: US, EU5, and China

8. Implications for Entrants and Investors

9. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures